Home Business Good News: The Stock Market Has A Leader Again

Good News: The Stock Market Has A Leader Again

When you purchase through our sponsored links, we may earn a commission. By using this website you agree to our T&Cs.

Where are the stock market leaders?

I asked this all-important question in a recent RiskHedge Report… and the answer I found was not good.

A healthy market needs at least one strong sector to lead it higher.

Unfortunately, my analysis showed we were in a leaderless market.

But things have changed.

One red-hot group of stocks is soaring… and looks to be in the early stages of a multi-month, or even multi-year rally.

It relates to some huge news that just came out:

Get The Full Ray Dalio Series in PDF

Get the entire 10-part series on Ray Dalio in PDF. Save it to your desktop, read it on your tablet, or email to your colleagues

Q3 2022 hedge fund letters, conferences and more


Find A Qualified Financial Advisor

Finding a qualified financial advisor doesn't have to be hard. SmartAsset's free tool matches you with up to 3 fiduciary financial advisors in your area in 5 minutes.

Each advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests.

If you're ready to be matched with local advisors that can help you achieve your financial goals, get started now.

A Breakthrough Treatment For Alzheimer's

  • Scientists seem to have found a breakthrough treatment for Alzheimer’s, slowing progression of the disease by almost 30%...

Biogen (NASDAQ:BIIB) and its Japanese partner Eisai (OTCMKTS:ESALY) have developed “lecanemab,” a drug to treat Alzheimer’s. They’re claiming results from a Phase 3 trial slowed cognitive decline by 27%.

That’s an INCREDIBLE discovery—and it could get even better.

These are results from initial trials...

Which means that as scientists perfect lecanemab, they could slow down cognitive decline even more.

Alzheimer’s has proven a very, very difficult disease to treat. There have been a lot of “false start” treatments that looked promising at the start… but ended up being disappointing.

This looks, and hopefully is, different. Experts are calling these results a “historic moment.”

And news of the trial triggered a powerful rally in biotech stocks…

Biogen jumped 40% in one day, while ESALY soared nearly 60%.

The news also sparked a massive rally in other stocks related to Alzheimer’s. Acumen Pharmaceuticals (NASDAQ:ABOS) surged 104% in a day, while Prothena Corp. (NASDAQ:PRTA) soared 88%.

Breakthroughs like this are why people invest in biotech stocks…

Few other sectors give you a shot at 50‒100% gains overnight from a world-changing discovery.

And while those quick gains are nice if you can find the right stocks.... I’m more interested in biotech for another reason...

Biotech Stocks Are Leading The Stock Market

  • In short: Biotech stocks are asserting themselves as the next great LEADERS of the stock market.

Like growth stocks, biotech stocks topped out well before the broad market did.

Both major biotech ETFs, iShares Biotechnology ETF (NASDAQ:IBB) and SPDR S&P Biotech ETF (NYSEARCA:XBI), topped out in February 2021... 10 months before the S&P 500 topped out.

So, it wouldn’t surprise me at all if the bear market in biotech stocks ends long before the major indices stop falling.

Some biotech stocks are already outperforming the market in a big way.

Since June, Biotech has been one of the strongest industries.

And many individual biotech stocks are trading near 52-week highs…

Just look at this chart of Vertex Pharmaceuticals (NASDAQ:VRTX), which creates medicines for people with life-threatening diseases. At the time of writing, VRTX is trading near all-time highs, despite the fact that the major indices have been taking a beating.

Vertex Pharmaceuticals

Source: StockCharts

Syndax Pharmaceuticals (NASDAQ:SNDX) is another biotech stock trading near all-time highs. Like Vertex, it looks poised for a breakout. It’s been trading sideways and building out a large base since the second half of 2020.

Syndax Pharmaceuticals

Source: StockCharts

You won’t find many stocks that look this good right now. Most stocks are getting crushed.

In the biotech sector, it’s a different world.

Countless biotech stocks are displaying remarkable relative strength right now. This is extremely valuable information.

Why? The stocks holding during today’s blood market will likely emerge as market leaders once the broad market volatility dies down.

  • In fact, biotech stocks have a long history of leading the market out of downturns…

The SPDR S&P Biotech ETF (NYSEARCA: XBI) has a history of rocketing higher following a bear market.

Following the 2009 recession, the XBI ETF shot up 500% in five years.

And after the COVID crash, XBI returned 180% in less than a year.

But now is not the time to take a “shotgun” approach to investing in biotech. I wouldn’t recommend buying XBI or IBB today.

I say this because the major indices remain under serious pressure. And it could be some time before volatility calms down.

Until that happens, it will be difficult for a major industry ETF to make progress. However, as we’ve seen lately, the very best biotech stocks can surge higher in any environment.

So, if you’re going to bet on biotech stocks right now, I would stick with the very best of the best. And keep your position sizes small.

  • You can find the best stocks by scanning for relative strength…

Specifically, I look for biotech stocks that are in strong uptrends.

Look for stocks trading above a rising 200-day moving average… at or near new all-time highs… and emerging from a multi-month or multi-year base.

Stocks ticking those boxes are likely great bets.

You may also want to focus on biotech stocks with several drugs in their pipeline. In other words, avoid biotech companies that are one-trick ponies. They’re much riskier than companies with diversified product lines. You can easily find out whether a company is diversified or not by checking out their website.

3 Breakthrough Stocks Set to Double Your Money in 2022

Get our latest report where we reveal our three favorite stocks that can hand you 100% gains as they disrupt whole industries. Get your free copy here.

Article By Justin Spittler, Mauldin Economics

Our Editorial Standards

At ValueWalk, we’re committed to providing accurate, research-backed information. Our editors go above and beyond to ensure our content is trustworthy and transparent.

Mauldin Economics

Want Financial Guidance Sent Straight to You?

  • Pop your email in the box, and you'll receive bi-weekly emails from ValueWalk.
  • We never send spam — only the latest financial news and guides to help you take charge of your financial future.